Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 9.63M -83.5% |
| Revenue (ttm) | 1.27M +161.1% |
| Net Income | -69.69M |
| EPS | -1.83 |
| Shares Out | 41.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,306,635 |
| Open | 0.2300 |
| Previous Close | 0.2369 |
| Day's Range | 0.2260 - 0.2430 |
| 52-Week Range | 0.1980 - 5.1400 |
| Beta | 0.40 |
| Analysts | Hold |
| Price Target | 1.00 (+332.53%) |
| Earnings Date | Aug 6, 2026 |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also deve... [Read more]
Financial Performance
In fiscal year 2026, Vistagen Therapeutics's revenue was $1.27 million, an increase of 161.11% compared to the previous year's $486,000. Losses were -$69.69 million, 35.5% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $1.0, which is an increase of 332.53% from the latest price.
News
Vistagen Therapeutics Transcript: Study update
The PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder did not meet primary or secondary endpoints in the overall population, but post-hoc analyses showed significant benefit in patients with very severe anxiety. Plans are underway to pursue a new registrational pathway using LSAS as the primary endpoint, supported by pooled data and favorable safety results.
Vistagen Therapeutics Press release: Study update
Vistagen Therapeutics issued a press release on June 30, 2026, disclosing material business information to investors.
Vistagen announces fasedienol did not achieve primary endpoint
Vistagen (VTGN) announced the topline results of the PALISADE-4 Phase 3 trial of intranasal fasedienol for the acute treatment of social anxiety disorder. In the overall trial population, fasedienol d...
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings release: Q4 2026
Vistagen Therapeutics released its Q4 2026 earnings on June 15, 2026, summarizing the period's financial results.
Vistagen Therapeutics Annual report: Q4 2026
Vistagen Therapeutics has published its Q4 2026 annual report on June 15, 2026.
Vistagen announces fasedienol achieves minimum patient exposures
Vistagen (VTGN) announced that the Company’s clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended un...
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen to Participate in Jefferies 2026 Global Healthcare Conference.
Vistagen Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The session highlighted advances in intranasal neuroscience candidates, with fasedienol leading in SAD treatment and key phase III data for PALISADE-4 expected soon. Pipeline assets itruvone and refisolone show promise in MDD and menopausal hot flashes, with cash runway into 2027.
Vistagen appoints Angelov as Chief Medical Officer
Vistagen (VTGN) announced the appointment of Angel Angelov, MD, MBA, as Chief Medical Officer, CMO, effective May 18, 2026. Dr. Angelov most recently served as CMO at Theranica Published first…
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new cla...
Vistagen reports preliminary positive data on ongoing PALISADE-3 study
Vistagen (VTGN) announced preliminary positive data from the ongoing open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol for the acute treatment of social anxiety disorder. In a...
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen announces completion of last patient visit in PALISADE-4 study
Vistagen (VTGN) announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company’s Phase 3 clinical trial evaluating ...
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
AbCellera target is profile more attractive than Vistagen, says JonesResearch
JonesResearch notes that Vistagen (VTGN) received an FDA “Study May Proceed” letter enabling further Phase 2 development of intranasal refisolone for menopausal vasomotor symptoms, also known as hot f...
Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing
Vistagen (VTGN) announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration under its U.S. Investigational New Drug application for refisolone nasal spray, the Company...
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
Fasedienol is advancing in phase III for social anxiety disorder, with PALISADE-4 results expected in the first half of the year. AI-driven analytics and operational improvements are being applied to enhance trial outcomes, while a robust data package and additional pipeline assets support future regulatory and clinical milestones.
Vistagen to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a pipeline of non-systemic, intranasal drug candidates targeting large unmet needs in neuropsychiatry and women's health. Lead asset Fasedienol showed positive phase III results in social anxiety disorder, with further pivotal data expected in H1 2026. AI-driven trial optimization and multiple regulatory strategies are being pursued.
Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims
A class action lawsuit was filed against Vistagen Therapeutics ($VTGN) on January 15, 2026. Plaintiffs in the federal securities class action allege that they acquired Vistagen stock at artificially i...